Historical data shows that a consistent $500 monthly investment into Kalaris Therapeutics Inc (KLRS) starting in 2020 would have turned a total investment of $18K into $12K today. This represents a total return of -30.8% over the 6-year period, compounding through dividend reinvestment and market growth.
The Impact of Dividend Reinvestment (DRIP)
Kalaris Therapeutics Inc does not currently pay a notable dividend. For growth-focused stocks like KLRS, dollar cost averaging relies entirely on price appreciation. Over the 6-year period, the strategy successfully captured the stock's price movements, resulting in a final portfolio value of $12K without the need for dividend reinvestment.
KLRS vs. S&P 500 (SPY) Benchmark
When comparing this dollar cost averaging strategy against a broad market index,KLRS underperformed the S&P 500 ETF (SPY). The same $500 monthly contributions into SPY would have grown to $22K, compared to KLRS's $12K.